Oxcarbazepine antinociception in animals with inflammatory pain or painful diabetic neuropathy

Clinical and Experimental Pharmacology and Physiology

Volumn 31, Issue 1-2, 2004, Pages 57-64

  Kiguchi, Sumiyoshi ^a   Imamura, Takahiro ^a   Ichikawa, Kiyoshi ^a   Kojima, Masami ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Carbamazepine; Mexiletine; Morphine; Oxcarbazepine; Painful diabetic neuropathy; Sodium channels; Streptozotocin

Indexed keywords

CARBAMAZEPINE; CARRAGEENAN; FORMALDEHYDE; MEXILETINE; MORPHINE; OXCARBAZEPINE; STREPTOZOCIN; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DIABETIC NEUROPATHY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG WITHDRAWAL; EXPERIMENTAL MODEL; GLUCOSE BLOOD LEVEL; HYPERALGESIA; INJECTION; INTERMETHOD COMPARISON; MALE; MECHANICAL HYPERPLASIA; MOUSE; NONHUMAN; PAIN; PAIN THRESHOLD; PAW EDEMA; RAT; TAIL FLICK TEST; THERMAL HYPERALGESIA;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CARBAMAZEPINE; CARRAGEENAN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; FORMALDEHYDE; HEAT; INFLAMMATION; MALE; MEXILETINE; MICE; MORPHINE; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME;

EID: 1242337435     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2004.03950.x     Document Type: Article

References (39)

1. Pfeifer MA, Ross DA, Schrage JP et al. A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care 1993; 16: 1103-15.
2. Kamei J, Ohhashi Y, Aoki T, Kawashima N, Kasuya Y. Streptozotocin- induced diabetes selectively alters the potency of analgesia produced by mu-opioid agonists, but not by delta-and kappa-opioid agonists. Brain Res. 1992; 571: 199-203.
3. Tandan R, Lewis GA, Krusinski PB, Badger GB, Fries TJ. Topical capsaicin in painful diabetic neuropathy. Diabetes Care 1992; 15: 8-14.
4. Kastrup J, Petersen P, Dejgård A, Angelo HR, Hilsted J. Intravenous lidocaine infusion: A new treatment of chronic painful diabetic neuropathy? Pain 1987; 28: 69-75.
5. Dejgård A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988; i: 9-11.
6. Saudeck CD, Werns S, Reidenberg MM. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin. Pharmacol. Ther. 1977; 22: 196-9.
7. Rull JA, Quibrera R, González-Millán H, Castañeda OL. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): Double blind crossover trial. Diabetologia 1989; 5: 215-18.
8. Blom S. Trigeminal neuralgia: Its treatment with a new anticonvulsant drug. Lancet 1962; i: 839-40.
9. Tanelian DL, Brose WG. Neuropathic pain can be relieved by drugs that are use-dependent sodium channel blockers. Lidocaine, carbamazepine, and mexiletine. Anesthesiology 1991; 74: 949-51.
10. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 1989; 3: 70-6.
11. Schwabe S. Oxcarbazepine: Clinical development program. Epilepsia 1994; 35 (Suppl.): S51-3.
12. Schauf CL, Davis FA, Marder JA. Effects of carbamazepine on the ionic conductance of Myxicola giant axons. J. Pharmacol. Exp. Ther. 1974; 189: 538-43.
13. 3H] batrachotoxin A 20-α-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmacol. 1982; 22: 627-35.
14. Ichikawa K, Koyama N, Kiguchi S, Kojima M, Yokota K. Inhibitory effect of oxcarbazepine on high-frequency firing in peripheral nerve fibers. Eur. J. Pharmacol. 2001; 420: 119-22.
15. Kiguchi S, Ichikawa K, Kojima M. Suppressive effects of oxcarbazepine on tooth pulp-evoked potentials recorded at the trigeminal spinal tract nucleus in cats. Clin. Exp. Pharmacol. Physiol. 2001; 28: 169-75.
16. Zimmerman M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109-10.
17. Randall LO, Sellito JJ. A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. 1957; 111: 409-19.
18. Dewey WL, Harris LS, Howes JP, Nuite JA. The effect of various neurohumoral modulators on the activity of morphine and the narcotic antagonists in the tail-flick and phenylquinone tests. J. Pharmacol. Exp. Ther. 1970; 175: 435-40.
19. Aley KO, Levine JD. Rapid onset pain induced by intravenous streptozotocin in the rat. J. Pain 2001; 2: 146-50.
20. Cameron NE, Cotter MA, Low PA. Nerve blood flow in early experimental diabetes in rats: Relation to conduction deficits. Am. J. Physiol. 1991; 261: E1-8.
21. Ohsawa M, Kamei J. Possible involvement of spinal protein kinase C in thermal allodynia and hyperalgesia in diabetic mice. Eur. J. Pharmacol. 1999; 372: 221-8.
22. + channels in pain pathways. Trends Pharmacol. Sci. 2001; 22: 27-31.
23. Craner MJ, Klein JP, Renganathan M, Black JA, Waxman SG. Changes of sodium channel expression in experimental painful diabetic neuropathy. Ann. Neurol. 2002; 52: 786-92.
24. Courtney KR. Comparative actions of mexiletine on sodium channels in nerve, skeletal and cardiac muscle. Eur. J. Pharmacol 1981; 74: 9-18.
25. Waldmeier PC, Bauman PA, Wicki P, Feldtrauer JJ, Stierlin C, Schmutz M. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 1995; 45: 1907-13.
26. Zhang X, Bao L, Shi TJ, Ju G, Elde R, Hökfelt T. Down-regulation of μ-opioid receptors in rat and monkey dorsal root ganglion neurons and spinal cord after peripheral axotomy. Neuroscience 1998; 82: 223-40.
27. Kamei J, Hitosugi H, Kawashima N, Aoki T, Ohhashi Y, Kasuya Y. Antinociceptive effect of mexiletine in diabetic mice. Res. Commun. Chem. Pathol. Pharmacol. 1992; 77: 333-8.
28. 1-opioid receptors in the antinociceptive responses in mice. Res. Commun. Chem. Pathol. Pharmacol. 1995; 80: 153-62.
29. Lembeck F, Holzer P. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch. Pharmacol. 1979; 310: 175-83.
30. Ohkubo T, Shibata M, Takahashi H, Inoki R. Roles of substance P and somatostatin on transmission of nociceptive information induced by formalin in spinal cord. J. Pharmacol. Exp. Ther. 1989; 252: 1261-8.
31. Hunskaar S, Berge OG, Hole K. Dissociation between antinociceptive and anti-inflammatory effects of acetylsalicylic acid and indomethacin in the formalin test. Pain 1986; 25: 125-32.
32. Bianchi M, Rossoni G, Sacerdote P, Panerai AE, Berti F. Carbamazepine exerts anti-inflammatory effects in the rat. Eur. J. Pharmacol. 1995; 294: 71-4.
33. Kamei J, Hitosugi H, Kasuya Y. Effects of mexiletine on formalin-induced nociceptive responses in mice. Res. Commun. Chem. Pathol. Pharmacol 1993; 80: 153-6.
34. Marangos PJ, Post RM, Zander K, Parma A, Weiss S. Specific and potent interactions of carbamazepine with brain adenosine receptors. Eur. J. Pharmacol. 1983; 93: 175-82.
35. Arrigoni E, Rainnie DG, McCarley RW, Greene RW. Adenosine-mediated presynaptic modulation of glutamatenergic transmission in the laterodorsal tegmentum. J. Neurosci. 2001; 21: 1076-85.
36. 1 receptors reduce release from excitatory but not inhibitory synaptic inputs onto lateral neurons. J. Neurosci. 2001; 21: 6308-20.
37. Poon A, Sawynok J. Antinociception by adenosine analogs and adenosine kinase inhibitor: Dependence on formalin concentration. Eur. J. Pharmacol. 1995; 286: 177-84.
38. 1 receptor mediated antinociception in the tail flick latency model in mice. Methods Find. Exp. Clin. Pharmacol. 2000; 22: 37-41.
39. Kiguchi S, Aoyagi S, Ichikawa K, Masami K, Arita H. Pharmacological properties of KIN-493 produced antinociception in STZ-induced diabetic mice. Jpn. J. Pharmacol. 1998; 76 (Suppl.): 155 (Abstract).